Table 5.
Comparison of dose-dense temozolomide trials: response and survival
| Study | NOP | Response | OS | Survival since relapse | |||||
| Total | EFR | CR | ORR | BRR | MST mo (95% CI) | MST mo (95% CI) | 1-Year OS (95% CI) | MTTP (95% CI) | |
| Brandes153 | 33 | 33 | 3% | 9% | 61% | N/A | 9.1 (7.1 to 14.5) | 38% | 3.7 (2.8 to 6.3) |
| Strik155 | 18 | 18 | 17% | 22% | 61% | 16.4* (17.9†) | 8.35* (9.1†) (N/A) | N/A | N/A |
| Abacioglu156 | 16 | 14 | 0% | 7% | 57% | N/A | 7 (5.7 to 8.2) | 0% | 3.0 (1.8 to 4.2) |
| Berrocal157 | 47 | 27 | 0% | 7% | 38%* | N/A | 5.1 (3.7 to 8.5)‡ | N/A | 2.0 (0.9 to 3.1) |
| Norden154 | 55 | 54 | 0% | 13% | 48% | 11.7 (8.1 to 16.2) | N/A | N/A | 1.8 (1.8 to 2.8) |
| Sahinbas23 | 54 | 15 | 7% | 20% | 53% | 20.8 (15.2 to 25.1) | 7.7 (5.7 to 9.4)§ | 29.5% (15.5–43.6) | N/A |
*Corrected data (the originally reported survival in months is derived from weeks by division to 4 (eg, 32.8 weeks=8.2 months), which overprices survival for 9%).
†Originally reported data (without correction).
‡For the complete sample of 47 patients, including 27 GBM and 20 WHO III tumours.
§Since first mEHT (not since relapse).
CR, complete response; BRR, beneficial response rate (ORR+stable disease); EFR, estimated for response; MST, median survival time (Kaplan-Meier estimation); MTTP, median time to progression; N/A, not available; NOP, number of patients; ORR, objective response rate (CR+partial response); OS, overall survival.